4-biphenyl-3-yl-7-chloro-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester | 870238-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-biphenyl-3-yl-7-chloro-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester
• 英文别名: methyl 7-chloro-4-(3-phenylphenyl)thieno[2,3-c]pyridine-2-carboxylate
• CAS: 870238-40-7
• 化学式: C₂₁H₁₄ClNO₂S
• 分子量: 379.867
• InChiKey: NDRWCLXZJKLGEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-biphenyl-3-yl-7-chloro-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 在 二苯甲酮亚胺 、 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 7-amino-4-biphenyl-3-yl-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production

  摘要：

  COT (Tpl2 in mice) is a serine/threonine MAP3 kinase that regulates production of TNF-alpha and other pro-inflammatory cytokines such as IL-1 beta via the ERK/MAP kinase pathway. As TNF-alpha and IL-1 beta are clinically validated targets for therapeutic intervention in rheumatoid arthritis (RA), blocking COT provides a potential avenue for amelioration of disease. Herein we describe identification of a cellular active selective small molecule inhibitor of COT kinase. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.088
• 作为产物：
  描述：

  methyl 4-bromo-7-chlorothieno[2,3-c]pyridine-2-carboxylate 、 3-联苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 0.25h， 以83%的产率得到4-biphenyl-3-yl-7-chloro-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production

  摘要：

  COT (Tpl2 in mice) is a serine/threonine MAP3 kinase that regulates production of TNF-alpha and other pro-inflammatory cytokines such as IL-1 beta via the ERK/MAP kinase pathway. As TNF-alpha and IL-1 beta are clinically validated targets for therapeutic intervention in rheumatoid arthritis (RA), blocking COT provides a potential avenue for amelioration of disease. Herein we describe identification of a cellular active selective small molecule inhibitor of COT kinase. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.088

文献信息

• Kinase inhibitors as therapeutic agents
  申请人：Cusack Kevin

  公开号：US20060074102A1

  公开（公告）日：2006-04-06

  A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

  式(I)化合物或其药学上可接受的盐，其中取代基如本文所定义，可用作激酶抑制剂。
• KINASE INHIBITORS AS THERAPEUTIC AGENTS
  申请人：ABBOTT LABORATORIES

  公开号：EP1753428A2

  公开（公告）日：2007-02-21
• [EN] KINASE INHIBITORS AS THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS DE KINASES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：ABBOTT LAB

  公开号：WO2005110410A2

  公开（公告）日：2005-11-24

  A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
• Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production
  作者：Kevin Cusack、Hamish Allen、Agnieszka Bischoff、Anca Clabbers、Richard Dixon、Shannon Fix-Stenzel、Michael Friedman、Yvette Gaumont、Dawn George、Thomas Gordon、Pintipa Grongsaard、Bernd Janssen、Yong Jia、Maria Moskey、Christopher Quinn、Andres Salmeron、Christine Thomas、Grier Wallace、Neil Wishart、Zhengtian Yu

  DOI：10.1016/j.bmcl.2009.01.088

  日期：2009.3

  COT (Tpl2 in mice) is a serine/threonine MAP3 kinase that regulates production of TNF-alpha and other pro-inflammatory cytokines such as IL-1 beta via the ERK/MAP kinase pathway. As TNF-alpha and IL-1 beta are clinically validated targets for therapeutic intervention in rheumatoid arthritis (RA), blocking COT provides a potential avenue for amelioration of disease. Herein we describe identification of a cellular active selective small molecule inhibitor of COT kinase. (C) 2009 Elsevier Ltd. All rights reserved.